Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation

Clin Nucl Med. 2021 Feb 1;46(2):144-145. doi: 10.1097/RLU.0000000000003452.

Abstract

Radiopharmaceutical extravasation is a known nuclear medicine adverse effect, mostly with no complication in case of diagnostic radiopharmaceutical. However, a therapeutic radiopharmaceutical extravasation may have clinical consequences and must be treated quickly and effectively. We report here a case of 177Lu-DOTA0-Tyr3-octreotate extravasation.

Publication types

  • Case Reports

MeSH terms

  • Coordination Complexes / adverse effects*
  • Coordination Complexes / metabolism*
  • Humans
  • Male
  • Octreotide / adverse effects
  • Octreotide / analogs & derivatives*
  • Octreotide / metabolism
  • Radionuclide Imaging

Substances

  • 177Lu-DOTA-octreotate
  • Coordination Complexes
  • Octreotide